Syma Iqbal1, Shannon McDonough2, Heinz-Josef Lenz1, David Ilson3, Barbara Burtness4, Chaitali S Nangia5, Afsaneh Barzi1, Charles J Schneider6, Jane Jijun Liu7, Efrat Dotan8, Katherine A Guthrie2, Howard S Hochster9. 1. University of Southern California, Los Angeles, CA. 2. SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA. 3. Memorial Sloan Kettering Cancer Center, New York, NY. 4. Yale University School of Medicine and Yale Cancer Center, New Haven, CT. 5. University of California Irvine, Orange, CA. 6. University of Pennsylvania, Newark, DE. 7. Illinois Cancer Care, Peoria, IL. 8. Fox Chase Cancer Center, Philadelphia, PA. 9. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
Abstract
PURPOSE:Platinum-based therapy is the standard of care in patients who have HER2-negative, advanced esophagogastric cancer (AEGC). Retrospective data suggest that intratumoral ERCC1 levels may determine platinum sensitivity. A randomized, phase II study was performed in patients with AEGC to explore whether the efficacy of a platinum-based therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) versus a non-platinum-containing regimen of irinotecan and docetaxel (IT) differed according to ERCC1 levels. PATIENTS AND METHODS: Overall, 202 untreated patients with HER2-negative AEGC and a Zubrod performance status of 0-1 were evaluated prospectively for mRNA expression of ERCC1 level and then randomly assigned to FOLFOX or IT, stratified by the intratumoral statuses of ERCC1 low (< 1.7) or high (≥ 1.7). Objectives were to assess progression-free survival (PFS) and overall survival (OS) in all patients treated with FOLFOX compared with IT, stratified by low and high ERCC1 levels, and to assess for interactive effects between ERCC1 expression and treatment arm. RESULTS: Eighty-six percent of patients had ERCC1 values < 1.7. Thus, evaluation of the ERCC1-high subgroup was limited. Grade ≥ 3 anemia, dehydration, diarrhea, and fatigue were greater in patients with IT. Occurrences of grade ≥ 3 neuropathy and decreased neutrophils were greater in patients with FOLFOX. In all patients, FOLFOX had a statistically superior median PFS compared with IT (5.7 v 2.9 months; hazard ratio, 0.68; P = .02). In patients with ERCC1 levels < 1.7 receiving FOLFOX, PFS and response rate were statistically superior to IT, with no significant difference in OS. CONCLUSION: The evaluation of ERCC1 in patients with upper GI tumors was thwarted by an overwhelming predominance of low ERCC1 mRNA expression. Nonetheless, distribution of treatment effects on PFS did not vary with expression. For all patients and for those with low ERCC1 expression, FOLFOX was superior in efficacy to IT.
RCT Entities:
PURPOSE:Platinum-based therapy is the standard of care in patients who have HER2-negative, advanced esophagogastric cancer (AEGC). Retrospective data suggest that intratumoral ERCC1 levels may determine platinum sensitivity. A randomized, phase II study was performed in patients with AEGC to explore whether the efficacy of a platinum-based therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) versus a non-platinum-containing regimen of irinotecan and docetaxel (IT) differed according to ERCC1 levels. PATIENTS AND METHODS: Overall, 202 untreated patients with HER2-negative AEGC and a Zubrod performance status of 0-1 were evaluated prospectively for mRNA expression of ERCC1 level and then randomly assigned to FOLFOX or IT, stratified by the intratumoral statuses of ERCC1 low (< 1.7) or high (≥ 1.7). Objectives were to assess progression-free survival (PFS) and overall survival (OS) in all patients treated with FOLFOX compared with IT, stratified by low and high ERCC1 levels, and to assess for interactive effects between ERCC1 expression and treatment arm. RESULTS: Eighty-six percent of patients had ERCC1 values < 1.7. Thus, evaluation of the ERCC1-high subgroup was limited. Grade ≥ 3 anemia, dehydration, diarrhea, and fatigue were greater in patients with IT. Occurrences of grade ≥ 3 neuropathy and decreased neutrophils were greater in patients with FOLFOX. In all patients, FOLFOX had a statistically superior median PFS compared with IT (5.7 v 2.9 months; hazard ratio, 0.68; P = .02). In patients with ERCC1 levels < 1.7 receiving FOLFOX, PFS and response rate were statistically superior to IT, with no significant difference in OS. CONCLUSION: The evaluation of ERCC1 in patients with upper GI tumors was thwarted by an overwhelming predominance of low ERCC1 mRNA expression. Nonetheless, distribution of treatment effects on PFS did not vary with expression. For all patients and for those with low ERCC1 expression, FOLFOX was superior in efficacy to IT.
Authors: Siow Ming Lee; Mary Falzon; Fiona Blackhall; James Spicer; Marianne Nicolson; Abhro Chaudhuri; Gary Middleton; Samreen Ahmed; Jonathan Hicks; Barbara Crosse; Mark Napier; Julian M Singer; David Ferry; Conrad Lewanski; Martin Forster; Sally-Ann Rolls; Arrigo Capitanio; Robin Rudd; Natasha Iles; Yenting Ngai; Michael Gandy; Rachel Lillywhite; Allan Hackshaw Journal: J Clin Oncol Date: 2016-11-28 Impact factor: 44.544
Authors: Lawrence P Leichman; Bryan H Goldman; Pierre O Bohanes; Heinz J Lenz; Charles R Thomas; Kevin G Billingsley; Christopher L Corless; Syma Iqbal; Philip J Gold; Jacqueline K Benedetti; Kathleen D Danenberg; Charles D Blanke Journal: J Clin Oncol Date: 2011-10-24 Impact factor: 44.544
Authors: David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman Journal: N Engl J Med Date: 2008-01-03 Impact factor: 91.245
Authors: Manuel Cobo; Dolores Isla; Bartomeu Massuti; Ana Montes; Jose Miguel Sanchez; Mariano Provencio; Nuria Viñolas; Luis Paz-Ares; Guillermo Lopez-Vivanco; Miguel Angel Muñoz; Enriqueta Felip; Vicente Alberola; Carlos Camps; Manuel Domine; Jose Javier Sanchez; Maria Sanchez-Ronco; Kathleen Danenberg; Miquel Taron; David Gandara; Rafael Rosell Journal: J Clin Oncol Date: 2007-07-01 Impact factor: 44.544
Authors: Peter C Enzinger; Barbara Ann Burtness; Donna Niedzwiecki; Xing Ye; Kathe Douglas; David H Ilson; Victoria Meucci Villaflor; Steven J Cohen; Robert J Mayer; Alan Venook; Al Bowen Benson; Richard M Goldberg Journal: J Clin Oncol Date: 2016-07-05 Impact factor: 44.544